青黄散联合化疗治疗急性髓性白血病临床研究

Efficacy of Qinghuang Powder combined with chemotherapy on treatment of AML

目的探讨青黄散联合化疗治疗急性髓性白血病(AML)的疗效。方法选取60例AML患者,随机分为两组,观察组(31例)给予青黄散联合DA化疗方案,对照组(29例)单纯给予DA化疗方案。观察比较两组治疗后1年的疗效、外周血象、随访1年期间不良反应情况和2年内生存率。结果治疗1年后,观察组有效率明显高于对照组(P<0.05);与治疗前相比,治疗后两组血红蛋白水平均上升(P<0.05),但两组间比较无统计学差异(P>0.05);治疗后两组白细胞计数和血小板计数均下降(P<0.05),且观察组数值均明显低于对照组(P<0.05);随访1年期间,两组在胃肠道不适、四肢水肿、恶心、腹痛、便血、皮疹等不良反应发生率方面比较,没有统计学差异(P>0.05);随访2年期间,第1年两组生存率无统计学差异(P>0.05),第2年,观察组生存率明显高于对照组(P<0.05)。结论青黄散联合化疗对AML具有较好的治疗效果,能显著抑制白细胞增殖,提高患者2年生存率,对正常血液功能影响小,未增加不良反应,值得临床推广使用。

Objective To explore the efficacy of Qinghuang Powder combined with chemotherapy on the treatment of acute myelogenous leukemia （AML）. Methods A total of 60 patients with AML were selected and divided into two groups according to whether or not Qinghuang Powder was used： the observation group （n=31）, which was given Qinghuang powder combined with DA chemotherapy and the control group （n=29）, which was given DA chemotherapy only. The efficacy and peripheral hemogram one year after the treatment, the incidence of adverse reactions during the first-year follow-up visit and the survival rate within the two years in the two groups were observed and compared. Results One year after the treatment, the effective rate in the observation group was higher than that in the control group （P 〈 0.05）. Compared with the values before the treatment, the levels of hemoglobin in the two groups increased after treatment （P 〈 0.05）, but there was no significance difference between the two groups （P 〉 0.05）. The leucocyte count and platelet count in the two groups after the treatment decreased significantly （P 〈 0.05） and the value in the observation group were much lower than those in the control group （P 〈 0.05）. During the first-year follow-up visit, there was no statistical significance in gastrointestinal discomfort, edema, nausea, pain, hematochezia, rash and other adverse reactions between the two groups （P 〉 0.05）. After two-year follow-up visit, there was no statistical significance in the survival rate between the two groups in the first year （P 〉 0.05）, but the survival rate in the observation group was higher than that in the control group in the second year （P 〈 0.05）. Conclusion Qinghuang Powder combined with chemotherapy has good efficacy on AML, can significantly inhibit the proliferation of leucocyte, improve the two-year survival rate of patients but impose minor impacts on normal blood function without increasing any adverse reactions. Therefore, it was worthy of clinical popularization and application.